|
1
|
Deng Y, Bi R, Zhu Z, Li S, Xu B, Rather WA
and Wang C: A surveillance, epidemiology and end results database
analysis of the prognostic value of organ-specific metastases in
patients with advanced prostatic adenocarcinoma. Oncol Lett.
18:1057–1070. 2019.PubMed/NCBI
|
|
2
|
Surveillance Epidemiology, End Results
(SEER) Program, . SEER*Stat Database: Incidence-SEER Research Data,
8 Registries, Nov 2024 Sub (1975–2022). National Cancer Institute,
Division of Cancer Control and Population Sciences, Surveillance
Research Program. Released. April. 2025, Available from:.
www.seer.cancer.gov
|
|
3
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR and Humphrey PA; Grading Committee, : The 2014
International society of urological pathology (ISUP) consensus
conference on Gleason grading of prostatic carcinoma: Definition of
grading patterns and proposal for a new grading system. Am J Surg
Pathol. 40:244–252. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei H, Miao J, Cui J, Zheng W, Chen X,
Zhang Q, Liu F, Mao Z, Qiu S and Zhang D: The prognosis and
clinicopathological features of different distant metastases
patterns in renal cell carcinoma: Analysis based on the SEER
database. Sci Rep. 11:178222021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shiota M, Matsubara N, Kato T, Eto M,
Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, et
al: Genomic characterization of metastatic patterns in prostate
cancer using circulating tumor DNA data from the SCRUM-Japan
MONSTAR SCREEN project. J Liq Biopsy. 7:1002822024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Furubayashi N, Negishi T, Sakamoto N,
Shimokawa H, Morokuma F, Song Y, Hori Y, Tomoda T, Tokuda N, Seki
N, et al: Organ-specific tumor response to pembrolizumab in
advanced urothelial carcinoma after Platinum-based chemotherapy.
Onco Targets Ther. 14:1981–1988. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhuang W, Li Y, Chen P, Wang J, Liu W and
Chen J: Do renal cell carcinoma patients with brain metastases
still need nephrectomy? Int Urol Nephrol. 51:941–949. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hamadi R, Karam I, Khan S, Homsy S and
Luhrs C: Tumour-To-Tumour metastasis: A rare case of prostate
cancer metastasising to primary lung adenocarcinoma. Eur J Case Rep
Intern Med. 11:0045792024.PubMed/NCBI
|
|
9
|
Steindl A, Alpar D, Heller G, Mair MJ,
Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner JA, Schmidinger
M, Bock C, et al: Tumor mutational burden and immune infiltrates in
renal cell carcinoma and matched brain metastases. ESMO Open.
6:1000572021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sorrentino C, Yin Z, Ciummo S, Lanuti P,
Lu LF, Marchisio M, Bellone M and Di Carlo E: Targeting
Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and
host environment synergistically inhibits prostate cancer growth
and improves survival. J Immunother Cancer. 7:2012019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hakozaki K, Tanaka N, Takamatsu K,
Takahashi R, Yasumizu Y, Mikami S, Shinojima T, Kakimi K, Kamatani
T, Miya F, et al: Landscape of prognostic signatures and
immunogenomics of the AXL/GAS6 axis in renal cell carcinoma. Br J
Cancer. 125:1533–1543. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen J, Cao N, Li S and Wang Y:
Identification of a risk stratification model to predict overall
survival and surgical benefit in clear cell renal cell carcinoma
with distant metastasis. Front Oncol. 11:6308422021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Yang G, Zhao D, Wang J, Bai Y,
Peng Q, Wang H, Fang R, Chen G, Wang Z, et al: CD103-positive CSC
exosome promotes EMT of clear cell renal cell carcinoma: Role of
remote MiR-19b-3p. Mol Cancer. 18:862019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Petrozza V, Costantini M, Tito C,
Giammusso LM, Sorrentino V, Cacciotti J, Porta N, Iaiza A, Pastore
AL, Di Carlo A, et al: Emerging role of secreted miR-210-3p as
potential biomarker for clear cell renal cell carcinoma metastasis.
Cancer Biomark. 27:181–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Ma
S, Liu C, Zuo J, Zhou X, Quan C, et al: Loss of epithelial AR
increase castration resistant stem-like prostate cancer cells and
promotes cancer metastasis via TGF-β1/EMT pathway. Transl Androl
Urol. 9:1013–1027. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li W, Yang FQ, Sun CM, Huang JH, Zhang HM,
Li X, Wang GC, Zhang N, Che JP, Zhang WT, et al: circPRRC2A
promotes angiogenesis and metastasis through epithelial-mesenchymal
transition and upregulates TRPM3 in renal cell carcinoma.
Theranostics. 10:4395–4409. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu N, Wang Y, Wang K, Zhong B, Liao Y,
Liang J and Jiang N: Cathepsin K regulates the tumor growth and
metastasis by IL-17/CTSK/EMT axis and mediates M2 macrophage
polarization in castration-resistant prostate cancer. Cell Death
Dis. 13:8132022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen X, Jia Y, Zhang Y, Zhou D, Sun H and
Ma X: α5-nAChR contributes to epithelial-mesenchymal transition and
metastasis by regulating Jab1/Csn5 signalling in lung cancer. J
Cell Mol Med. 24:2497–2506. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao Q, Liu Y, Wu Y, Hu C, Sun L, Wang J,
Li C, Guo M, Liu X, Lv J, et al: Profilin 2 promotes growth,
metastasis, and angiogenesis of small cell lung cancer through
cancer-derived exosomes. Aging (Albany NY). 12:25981–25999. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Davoodvandi A, Darvish M, Borran S, Nejati
M, Mazaheri S, Reza Tamtaji O, Hamblin MR, Masoudian N and Mirzaei
H: The therapeutic potential of resveratrol in a mouse model of
melanoma lung metastasis. Int Immunopharmacol. 88:1069052020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Masuda C, Sugimoto M, Wakita D, Monnai M,
Ishimaru C, Nakamura R, Kinoshita M, Yorozu K, Kurasawa M, Kondoh O
and Yamamoto K: Bevacizumab suppresses the growth of established
non-small-cell lung cancer brain metastases in a hematogenous brain
metastasis model. Clin Exp Metastasis. 37:199–207. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berta J, Török S, Tárnoki-Zách J,
Drozdovszky O, Tóvári J, Paku S, Kovács I, Czirók A, Masri B,
Megyesfalvi Z, et al: Apelin promotes blood and lymph vessel
formation and the growth of melanoma lung metastasis. Sci Rep.
11:57982021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang B, Pan LY, Kang N and Shen XY: PP4R1
interacts with HMGA2 to promote non-small-cell lung cancer
migration and metastasis via activating MAPK/ERK-induced
epithelial-mesenchymal transition. Mol Carcinog. 59:467–477. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang B, Li Y, Wu Q, Xie L, Barwick B, Fu
C, Li X, Wu D, Xia S, Chen J, et al: Acetylation of KLF5 maintains
EMT and tumorigenicity to cause chemoresistant bone metastasis in
prostate cancer. Nat Commun. 12:17142021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shin SB, Jang HR, Xu R, Won JY and Yim H:
Active PLK1-driven metastasis is amplified by TGF-β signaling that
forms a positive feedback loop in non-small cell lung cancer.
Oncogene. 39:767–785. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gallazzi M, Baci D, Mortara L, Bosi A,
Buono G, Naselli A, Guarneri A, Dehò F, Capogrosso P, Albini A, et
al: Prostate cancer peripheral blood NK cells show enhanced CD9,
CD49a, CXCR4, CXCL8, MMP-9 production and secrete
monocyte-recruiting and polarizing factors. Front Immunol.
11:5861262020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li L, Zhao L, Yang J and Zhou L:
Multifaceted effects of LRP6 in cancer: Exploring tumor
development, immune modulation and targeted therapies. Med Oncol.
41:1802024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ruan T, Jiang L, Xu J and Zhou J:
Abiraterone suppresses irradiated lung cancer cells-induced
angiogenic capacities of endothelial cells. J Bioenerg Biomembr.
53:343–349. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang YC, Liu CT, Yu CY and Sung WW:
NPS-1034 exerts therapeutic efficacy in renal cell carcinoma
through multiple targets of MET, AXL, and TNFRSF1A signaling in a
metastatic model. Cells. 13:17132024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Greifenstein L, Kramer CS, Moon ES, Rösch
F, Klega A, Landvogt C, Müller C and Baum RP: From automated
synthesis to in vivo application in multiple types of
Cancer-clinical results with [68Ga]Ga-DATA5m.SA.FAPi.
Pharmaceuticals (Basel). 15:10002022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kraxner A, Braun F, Cheng WY, Yang TO,
Pipaliya S, Canamero M, Andersson E, Harring SV, Dziadek S, Bröske
AE, et al: Investigating the complex interplay between fibroblast
activation protein α-positive cancer associated fibroblasts and the
tumor microenvironment in the context of cancer immunotherapy.
Front Immunol. 15:13526322024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu W, Zhang X, Zhang W, Xiong M, Lin Y,
Chang M, Xu L, Lu Y, Liu Y and Zhang J: 19-Hydroxybufalin inhibits
non-small cell lung cancer cell proliferation and promotes cell
apoptosis via the Wnt/β-catenin pathway. Exp Hematol Oncol.
10:482021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Watts A, Singh B, Singh H, Kaur H, Bal A,
Vohra M, Arora SK and Behera D: 68Ga-pentixafor PET/CT
demonstrating in vivo CXCR4 receptor overexpression in rare lung
malignancies: Correlation with histologic and histochemical
findings. J Nucl Med Technol. 50:278–281. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Slania SL, Das D, Lisok A, Du Y, Jiang Z,
Mease RC, Rowe SP, Nimmagadda S, Yang X, Pomper MG, et al: Imaging
of fibroblast activation protein in cancer xenografts using novel
(4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based small molecules. J
Med Chem. 64:4059–4070. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Manawy SM, Faruk EM, Hindawy RF, Hassan
MM, Farrag DMG, Bashar MAE, Fouad H, Bagabir RA, Hassan DAA, Zaazaa
AM, et al: Modulation of the Sirtuin-1 signaling pathway in
doxorubicin-induced nephrotoxicity (synergistic amelioration by
resveratrol and pirfenidone). Tissue Cell. 87:1023302024.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng Y, Yang S, Si J, Zhao Y, Zhao M and
Ji E: Shashen-maidong decoction inhibited cancer growth under
intermittent hypoxia conditions by suppressing oxidative stress and
inflammation. J Ethnopharmacol. 299:1156542022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu X, Tang J, Peng L, Nie H, Zhang Y and
Liu P: Cancer-associated fibroblasts promote malignant phenotypes
of prostate cancer cells via autophagy: Cancer-associated
fibroblasts promote prostate cancer developmentt. Apoptosis.
28:881–891. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao F, Chen X, Li X, Deng C and Luo P: The
Pro-migratory and Pro-invasive roles of cancer-associated
fibroblasts secreted IL-17A in prostate cancer. J Biochem Mol
Toxicol. 39:e700472025. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li H, Ding J, Lu M, Liu H, Miao Y, Li L,
Wang G, Zheng J, Pei D and Zhang Q: CAIX-specific CAR-T cells and
sunitinib show synergistic effects against metastatic renal cancer
models. J Immunother. 43:16–28. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maolake A, Izumi K, Shigehara K,
Natsagdorj A, Iwamoto H, Kadomoto S, Takezawa Y, Machioka K,
Narimoto K, Namiki M, et al: Tumor-associated macrophages promote
prostate cancer migration through activation of the CCL22-CCR4
axis. Oncotarget. 8:9739–9751. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shi F, Sun MH, Zhou Z, Wu L, Zhu Z, Xia
SJ, Han BM, Zhao YY, Jing YF and Cui D: Tumor-associated
macrophages in direct contact with prostate cancer cells promote
malignant proliferation and metastasis through NOTCH1 pathway. Int
J Biol Sci. 18:5994–6007. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang C, Wang Y, Hong T, Ye J, Chu C, Zuo
L, Zhang J and Cui X: Targeting a positive regulatory loop in the
tumor-macrophage interaction impairs the progression of clear cell
renal cell carcinoma. Cell Death Differ. 28:932–951. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
O'Shaughnessy MJ, Murray KS, La Rosa SP,
Budhu S, Merghoub T, Somma A, Monette S, Kim K, Corradi RB, Scherz
A and Coleman JA: Systemic antitumor immunity by PD-1/PD-L1
Inhibition is potentiated by Vascular-targeted photodynamic therapy
of primary tumors. Clin Cancer Res. 24:592–599. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao Y, Peng X, Baldwin H, Zhang C, Liu Z
and Lu X: Anti-androgen therapy induces transcriptomic
reprogramming in metastatic castration-resistant prostate cancer in
a murine model. Biochim Biophys Acta Mol Basis Dis.
1867:1661512021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lv Z, Cui B, Huang X, Feng HY, Wang T,
Wang HF, Xuan YD, Li HZ, Ma X, Huang Y and Zhang X: FGL1 as a novel
mediator and biomarker of malignant progression in clear cell renal
cell carcinoma. Front Oncol. 11:7568432021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang Y, Wang X, Gu Y, Liu T, Zhao X,
Cheng S, Duan L, Huang C, Wu S and Gao S: Complement C3 of
tumor-derived extracellular vesicles promotes metastasis of RCC via
recruitment of immunosuppressive myeloid cells. Proc Natl Acad Sci
USA. 122:e24200051222025. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhu Y, Han CH, Yang YL, Xu JJ and Yu YW:
Metastatic renal cell carcinoma: A clinicopathological analysis of
196 cases. Zhonghua Bing Li Xue Za Zhi. 49:1255–1260. 2020.(In
Chinese). PubMed/NCBI
|
|
48
|
Herrington CS, Poulsom R and Coates PJ:
Recent advances in pathology: The 2019 annual review issue of the
journal of pathology. J Pathol. 247:535–538. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nguyen NJ, Sherman C, van der Kwast TH and
Downes MR: Aggressive prostatic adenocarcinoma with urothelial-like
morphology, with frequent CK7/CK20/HMWK expression and occasional
diffuse neuroendocrine features: A clinicopathologic study of 12
cases. Pathol Res Pract. 254:1551052024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhao H, Nolley R, Chan AMW, Rankin EB and
Peehl DM: Cabozantinib inhibits tumor growth and metastasis of a
patient-derived xenograft model of papillary renal cell carcinoma
with MET mutation. Cancer Biol Ther. 18:863–871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu W, Wang Y, Rao Q, Jiang Y, Zhang W and
Li Y: Xp11.2 translocation renal neoplasm with features of TFE3
rearrangement associated renal cell carcinoma and Xp11
translocation renal mesenchymal tumor with melanocytic
differentiation harboring NONO-TFE3 fusion gene. Pathol Res Pract.
215:1525212019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gong Y, Fan L, Fei X, Zhu Y, Du X, He Y,
Pan J, Dong B and Xue W: Targeted Next-generation sequencing
reveals heterogenous genomic features in viscerally metastatic
prostate cancer. J Urol. 206:279–288. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Strati A, Markou A, Kyriakopoulou E and
Lianidou E: Detection and molecular characterization of circulating
tumour cells: Challenges for the clinical setting. Cancers (Basel).
15:21852023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Dincman TA, Karam JAQ, Giordano A, Li H,
Drusbosky LM, Gourdin TS, Howe PH and Lilly MB: Genomic
amplifications identified by circulating tumor DNA analysis guide
prognosis in metastatic castration-resistant prostate cancer. Front
Oncol. 13:12022772023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Esposito A, Bardelli A, Criscitiello C,
Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M,
Goldhirsch A and Curigliano G: Monitoring tumor-derived cell-free
DNA in patients with solid tumors: Clinical perspectives and
research opportunities. Cancer Treat Rev. 40:648–655. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ying M, Mao J, Sheng L, Wu H, Bai G, Zhong
Z and Pan Z: Biomarkers for prostate cancer bone metastasis
detection and prediction. J Pers Med. 13:7052023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Botticelli A, Mezi S, Pomati G, Cerbelli
B, Cerbelli E, Roberto M, Giusti R, Cortellini A, Lionetto L,
Scagnoli S, et al: Tryptophan catabolism as immune mechanism of
primary resistance to Anti-PD-1. Front Immunol. 11:12432020.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kasi PM, Bucheit LA, Liao J, Starr J,
Barata P, Klempner SJ, Gandara D, Shergill A, Madeira da Silva L,
Weipert C, et al: Pan-cancer prevalence of microsatellite
Instability-High (MSI-H) identified by circulating tumor DNA and
Associated Real-world clinical outcomes. JCO Precis Oncol.
7:e23001182023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pollack M, Keating K, Wissinger E, Jackson
L, Sarnes E and Cuffel B: Transforming approaches to treating TRK
fusion cancer: Historical comparison of larotrectinib and
histology-specific therapies. Curr Med Res Opin. 37:59–70. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Markham A: Savolitinib: First approval.
Drugs. 81:1665–1670. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
de Bono JS, Mehra N, Scagliotti GV, Castro
E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, et
al: Talazoparib monotherapy in metastatic Castration-resistant
prostate cancer with DNA repair alterations (TALAPRO-1): An
open-label, phase 2 trial. Lancet Oncol. 22:1250–1264. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yap TA, Bardia A, Dvorkin M, Galsky MD,
Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, et
al: Avelumab plus talazoparib in patients with advanced solid
tumors: The JAVELIN PARP medley nonrandomized controlled trial.
JAMA Oncol. 9:40–50. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Danno T, Iwata S, Niimi F, Honda S, Okada
H and Azuma T: Nivolumab and ipilimumab combination immunotherapy
for patients with metastatic collecting duct carcinoma. Case Rep
Urol. 2021:99363302021.PubMed/NCBI
|
|
64
|
Liu C, Piao J and Shang Z:
Hyperprogressive disease after radiotherapy combined with anti-PD-1
therapy in renal cell carcinoma: A case report and review of the
literature. BMC Urol. 21:422021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Passaro A, Stenzinger A and Peters S:
Tumor mutational burden as a Pan-cancer biomarker for
immunotherapy: The limits and potential for convergence. Cancer
Cell. 38:624–625. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chen A, Zhang S, Xiong L, Xi S, Tao R,
Chen C, Li J, Chen J and Li C: Investigation of an Alternative
marker for hypermutability evaluation in different tumors. Genes
(Basel). 12:1972021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang C, Liu Y, Chen Z, Liu YI, Mao Q,
Zhang GE, Lin H, Zheng J and Li H: Current status, hotspots, and
trends in cancer prevention, screening, diagnosis, treatment, and
rehabilitation: A bibliometric analysis. Oncol Res. 33:1437–1458.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Afridi WA, Picos SH, Bark JM, Stamoudis
DAF, Vasani S, Irwin D, Fielding D and Punyadeera C: Minimally
invasive biomarkers for triaging lung nodules-challenges and future
perspectives. Cancer Metastasis Rev. 44:292025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Tabnak P, Kargar Z, Ebrahimnezhad M and
HajiEsmailPoor Z: A Bayesian meta-analysis on MRI-based radiomics
for predicting EGFR mutation in brain metastasis of lung cancer.
BMC Med Imaging. 25:442025. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Leivaditis V, Maniatopoulos AA, Lausberg
H, Mulita F, Papatriantafyllou A, Liolis E, Beltsios E, Adamou A,
Kontodimopoulos N and Dahm M: Artificial intelligence in thoracic
surgery: A review bridging innovation and clinical practice for the
next generation of surgical care. J Clin Med. 14:27292025.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tang F, Zha XK, Ye W, Wang YM, Wu YF, Wang
LN, Lyu LP and Lyu XM: Artificial intelligence-assisted
endobronchial ultrasound for differentiating between benign and
malignant thoracic lymph nodes: A meta-analysis. BMC Pulm Med.
25:3032025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang L, Yang D, Ye X and Bai C:
Successful application of artificial Intelligence-assisted analysis
of invasive pulmonary adenocarcinoma less than 6 mm in size: A case
report and literature review. Clin Respir J. 19:e700732025.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Talebi F, Gregucci F, Ahmed J, Ben Chetrit
N, D Brown B, Chan TA, Chand D, Constanzo J, Demaria S, I
Gabrilovich D, et al: Updates on radiotherapy-immunotherapy
combinations: Proceedings of 8th Annual ImmunoRad Conference.
Oncoimmunology. 14:25078562025. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Suzuki H, Maruya Y, Inomata S, Yamaguchi
H, Ozaki Y, Watanabe M, Fukuhara M, Muto S and Okabe N: Clinical
significance and future prospects of tertiary lymphoid structure in
lung cancer. Gan To Kagaku Ryoho. 52:628–632. 2025.(In Japanese).
PubMed/NCBI
|
|
75
|
Jahangir CA, Page DB, Broeckx G, Gonzalez
CA, Burke C, Murphy C, Reis-Filho JS, Ly A, Harms PW, Gupta RR, et
al: Image-based multiplex immune profiling of cancer tissues:
Translational implications. A report of the International
Immuno-oncology Biomarker Working Group on Breast Cancer. J Pathol.
262:271–288. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lee EJ, Chung HW, So Y, Kim IA, Kim HJ and
Lee KY: Recent advances in PET and radioligand therapy for lung
cancer: FDG and FAP. Cancers (Basel). 17:25492025. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hajikarimloo B, Mohammadzadeh I, Tos SM,
Habibi MA, Hashemi R, Hezaveh EB, Najari D, Hasanzade A, Hooshmand
M and Bana S: Machine learning in prediction of epidermal growth
factor receptor status in non-small cell lung cancer brain
metastases: A systematic review and meta-analysis. BMC Cancer.
25:8182025. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yu J, Kong X and Feng Y: Tumor
microenvironment-driven resistance to immunotherapy in non-small
cell lung cancer: Strategies for Cold-to-Hot tumor transformation.
Cancer Drug Resist. 8:212025.PubMed/NCBI
|
|
79
|
Shang D, Zhou Z, Shi R, Wang Z, Zhang P,
Peng F, Li H, Cheng G, Qin H, Xie Z, et al: Nanoparticle-based
strategy in CAR-T cell immunotherapy: Challenges, implications, and
perspectives. Mol Cancer. 24:2812025. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Rafii S, Mukherji D, Komaranchath AS,
Khalil C, Iqbal F, Abdelwahab SI, Abyad A, Abuhelwa AY, Gandikota L
and Al-Shamsi HO: Advancing CAR T-Cell therapy in solid tumors:
Current landscape and future directions. Cancers (Basel).
17:28982025. View Article : Google Scholar : PubMed/NCBI
|
